Valneva Receives Major Grant from CEPI to Enhance Global Accessibility to Chikungunya Vaccine

In a significant move to combat the global health threat posed by chikungunya, Valneva SE VALN, a France-based vaccine company, has been pledged up to $41.3 million in funding. This initiative comes as a collaborative effort between the Coalition for Epidemic Preparedness Innovations (CEPI) and the European Union. The substantial grant is aimed at furthering the reach of the company's chikungunya vaccine, IXCHIQ®, making it more accessible worldwide, especially in regions where the disease is prevalent.

Advancing Chikungunya Vaccine Accessibility

The generous grant from CEPI, supplemented by the European Union, is designed to catalyze the availability of IXCHIQ®, the world's pioneering chikungunya vaccine. With this financial boost, Valneva is expected to broaden the scope of its clinical trials to include demographic groups that are at heightened risk, such as children and pregnant women, thereby amplifying the vaccine's safety and efficacy data across varied populations.

Valneva: At the Forefront of Vaccine Innovation

As a frontrunner in the vaccine industry, Valneva SE (VALN) is dedicated to addressing urgent health threats through the development of preventive vaccines. Headquartered in Saint-Herblain, France, the company is committed to delivering innovative vaccine solutions to tackle infectious diseases that have historically been neglected. With the recent funding from CEPI, Valneva is poised to make significant strides in the global fight against chikungunya, a debilitating mosquito-borne disease with no current approved vaccine for prevention.

Valneva, CEPI, chikungunya, vaccine, funding